Testing a new questionnaire for memory and thinking worries, plus computer-based brain training
Tests a new screening tool for self-noticed cognitive decline in older adults.
Key facts
- Who runs it
- Istituti Clinici Scientifici Maugeri SpA
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 2 Aug 2022
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- cognitive training
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 55 who feel their memory or thinking has got worse, with no other cognitive or nerve problem. It tests a new screening questionnaire called MASCoD and cognitive training on a tablet.
- Age
- Over 55 years
- Sex
- All sexes
- Disease stage
- Self-reported decline in thinking or memory, not found by tests, with no other cognitive or neurological problem.
Main reasons for not taking part
- Serious health problems, such as severe heart or breathing problems, or cancer
- A past diagnosis of a psychiatric disorder (DSM-5)
- A past diagnosis of cognitive decline
- Major problems with seeing or hearing
- Not able to read and write
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- reported subjective cognitive decline without any other cognitive or neurological issue,
- Italian education,
- adult (> 55 years old),
- understanding of research aims,
- signed informed consent,
- participation on a voluntary and non-payied bases
Who cannot take part
- prior diagnosis of psychiatric disorders according to DSM-5,
- prior diagnosis of cognitive decline,
- serious clinical conditions (e.g. severe cardiac and respiratory problems, neoplasia)
- relevant visuo-perceptive or hearing deficits,
- illiteracy or relapse in illiteracy,
- refusal to partake in the research
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Subjective cognitive decline-SCD is a subclinical cognitive impairment subjectively experienced without being detectable from a diagnostic and neuropsychological perspective. It can negatively impact on patient's frailty and quality of life and it may be prodromal to severe cognitive impairment. Currently, only a few screening tools focusing mainly on memory complaints exist.
Read full original descriptionShow less
The aim of this study is to analyze if a new screening tool called MASCoD (Multidimensional Assessment of Subjective Cognitive Decline) can detect and monitor the SCD, predicting the risk of developing severe cognitive decline over time.
Specifically, the investigators have the following aims:
primary objectives:
1. To assess the construct validity and tune the clinical cutoffs of the new instrument through the correlation of MASCoD scores with neuropsychological evaluation and brain 18F-FDG-PET. 2. To assess the clinical validity (predictive capability) of the new instrument through a classification model (dependent variable: brain 18F-FDG-PET examination; independent variable: MASCoD; control variables: gender, age and neuropsychological evaluation).
Secondary objective:
To evaluate the suitability of MASCoD as tool for the monitoring of patients over time. Specifically, the investigators want to evaluate if the MASCoD score is able to assess the effects of a cognitive treatment and, in turn, to identify outpatients who most likely will benefit from it.
After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered by means of technological devices (Neurotablet).
At T1, all outpatients (experimental group and wait list control group) will be evaluated through MASCoD and the extensive neuropsychological evaluation for the second time.
The 2 groups in the trial
- rehabilitation groupTreatment being tested
Outpatients undergoing neurorehabilitation through Neurotablet
Treatment: cognitive training
- waiting listNo study treatment, for comparison
Outpatients not undergoing rehabilitation during the study. They will have the possibility to carry on the rehabilitation at the end of the study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Validation and Clinical Usability of a New Screening Tool: MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
- Plain-language title
- Testing a new questionnaire for memory and thinking worries, plus computer-based brain trainingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 13 November 2026